Lineage Cell Therapeutics, Inc. director Broadwood Partners, L.P. makes first open-market buy in 12 months: $770,700
An open-market purchase on Nov 17, reported to the SEC on Nov 19.
A Form 4 filed on Nov 19 shows Broadwood Partners, L.P. (Director) buying 1,000,000 Lineage Cell Therapeutics, Inc. shares worth $770,700 on Nov 17.
It is an open-market purchase (transaction code P) of common stock, the kind of trade insiders make with their own money. The trade was reported within two business days, as Section 16 requires.
After the trade, the filing lists 50,560,992 shares held. Other Lineage Cell Therapeutics, Inc. insiders have also bought: Five insiders made open-market purchases within 14 days, a pattern known as a cluster buy.
Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
|---|---|
| Insider | Broadwood Partners, L.P. |
| Role | Director |
| Transaction | Open-market purchase (code P) |
| Shares | 1,000,000 |
| Average price | $0.7707 |
| Value | $770,700 |
| Trade date | Nov 17, 2026 |
| Filed with the SEC | Nov 19, 2026, 5:58 PM ET |
| Shares held after | 50,560,992 |
| Ownership | Direct |
| Rule 10b5-1 plan | Not marked in the filing |
Open the full breakdown of this LCTX trade
See more large insider purchases · See where several insiders traded together
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.